Success Story: NAILG Demonstrates Research Significance to Secure NIW Approval for a Cancer Therapeutics Expert
Client’s Testimonial:
“Thank you again for all your support and assistance throughout my NIW petition.”
On October 3rd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a PhD Candidate in the Field of Cancer Therapeutics (Approval Notice).
General Field: Cancer Therapeutics
Position at the Time of Case Filing: PhD Candidate
Country of Origin: Ghana
State of Residence at the Time of Filing: Connecticut
Approval Notice Date: October 3rd, 2026
Processing Time: 10 months, 19 days (Premium Processing Upgrade Requested)
Case Summary:
Developing safer and more effective cancer treatments remains an important priority in medical research. For a researcher specializing in cancer therapeutics, this challenge formed the foundation of an EB-2 National Interest Waiver (NIW) petition successfully prepared by North America Immigration Law Group (NAILG). With a master’s degree in molecular medicine, the client had established expertise in cancer biology and innovative therapeutic approaches aimed at improving treatment effectiveness.
The client's proposed endeavor focused on studying cancer biology and developing more precise treatment strategies capable of targeting cancerous cells while reducing potential harm to healthy tissues. Our team emphasized the national importance of this research by connecting its potential applications to U.S. public health needs, advancements in cancer treatment, and the development of emerging biotechnology. We demonstrated how the client's continued contributions could support scientific progress beyond any single employer or research institution.
To establish the client's qualifications, we highlighted a scholarly record consisting of 3 peer-reviewed journal articles and 6 research abstracts, including 5 first-authored abstracts. The client's publications had received 59 citations, reflecting recognition within the scientific community. Rather than relying on citation numbers alone, we presented comparative evidence showing that 2 articles ranked among the top 10% and 1 among the top 20% most-cited publications in their respective field and publication years.
We further strengthened the petition by demonstrating how independent researchers had incorporated the client's findings into their own studies. These examples illustrated the relevance of the client's contributions to developing targeted therapeutic approaches and improving methods used in biomedical research. By connecting this independent recognition with the client's academic training and demonstrated research accomplishments, we established a foundation for arguing that the client was well positioned to advance the proposed endeavor.
The petition also explained why waiving the job offer and labor certification requirements would benefit the United States, particularly given the importance of continued research and collaboration in cancer therapeutics. Through this comprehensive presentation of the client's qualifications, research influence, and proposed contributions, we successfully secured I-140 NIW approval. This outcome supports the client's continued pursuit of research aimed at improving cancer treatment strategies and advancing biomedical innovation.